Off-target effects can have undesirable consequences in therapeutic CRISPR-Cas9 genome editing applications.
In this application note from Thermo Fisher Scientific, the authors detail their efforts to identify a Cas9 variant that would limit off-target edits, using a target-enriched GUIDE-seq (TEG-seq) to screen several Cas9 candidates. They present their development of a high-fidelity Cas9 protein, TrueCut HiFi Cas9, which was optimized for editing efficiency and showed higher fidelity than wild-type TrueCut Cas9 Protein v2 and other commercially available high-fidelity Cas9 proteins in a variety of cell types.
Offered Free by: Thermo Fisher Scientific
See All Resources from: Thermo Fisher Scientific